L-Tryptophan exhibits therapeutic function in a porcine model of dextran sodium sulfate (DSS)-induced colitis

Journal of Nutritional Biochemistry

Volumn 21, Issue 6, 2010, Pages 468-475

  Kim, Connie J ^a   Kovacs Nolan, Jennifer A ^a   Yang, Chengbo ^a   Archbold, Tania ^a   Fan, Ming Z ^a   Mine, Yoshinori ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Colitis; Dextran sodium sulfate (DSS); Inflammatory bowel disease (IBD); Inflammatory cytokine expression; L Tryptophan; Therapeutic

Indexed keywords

CASPASE 8; DEXTRAN SULFATE; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MANNITOL; PROTEIN BAX; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; DEXTRAN; SODIUM SULFATE; SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOMODULATION; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SWINE; WEIGHT GAIN; ANIMAL; APOPTOSIS; BODY WEIGHT; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; INFLAMMATION; METABOLISM; NUTRITIONAL SCIENCE; PERMEABILITY;

ANIMAL NUTRITION SCIENCES; ANIMALS; APOPTOSIS; BODY WEIGHT; COLITIS; DEXTRANS; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-6; MANNITOL; PERMEABILITY; SULFATES; SWINE; TRYPTOPHAN; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; SUS;

EID: 77952880348     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2009.01.019     Document Type: Article

References (58)

1. Podolsky D.K. Inflammatory bowel disease (1). N Engl J Med 1991, 325:928-937.
2. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001, 120:622-635.
3. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
4. Shanahan F. Nutrient tasting and signaling mechanisms in the gut V. Mechanisms of immunologic sensation of intestinal contents. Am J Physiol Gastrointest Liver Physiol 2000, 278:G191-G196.
5. Felley-Bosco E., Andre M. Proteomics and chronic inflammatory bowel diseases. Pathol Res Pract 2004, 200:129-133.
6. Nakamura K., Honda K., Mizutani T., Akiho H., Harada N. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006, 12:4628-4635.
7. Martland G.T., Shepherd N.A. Indeterminate colitis: definition, diagnosis, implications and a plea for nosological sanity. Histopathology 2007, 50:83-96.
8. Welcker K., Martin A., Kolle P., Siebeck M., Gross M. Increased intestinal permeability in patients with inflammatory bowel disease. Eur J Med Res 2004, 9:456-460.
9. Dieleman L.A., Palmen M.J., Akol H., Bloemena E., Pena A.S., Meuwissen S.G., et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998, 114:385-391.
10. Ardizzone S., Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005, 65:2253-2286.
11. Atreya R., Neurath M.F. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 2008, 1:175-182.
12. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
13. Present D.H., Meltzer S.J., Krumholz M.P., Wolke A., Korelitz B.I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989, 111:641-649.
14. Wang W.W., Qiao S.Y., Li D.F. Amino acids and gut function. Amino Acids 2008, Epub ahead of print. 10.1007/s00726-008-0152-4.
15. 13C]phenylalanine. Am J Clin Nutr 1998, 68:303-310.
16. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. Faseb J 1991, 5:2516-2522.
17. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999, 189:1363-1372.
18. Fallarino F., Grohmann U., Vacca C., Bianchi R., Orabona C., Spreca A., et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ 2002, 9:1069-1077.
19. Terness P., Bauer T.M., Rose L., Dufter C., Watzlik A., Simon H., et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002, 196:447-457.
20. Harding H.P., Novoa I., Zhang Y., Zeng H., Wek R., Schapira M., et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 2000, 6:1099-1108.
21. Munn D.H., Sharma M.D., Baban B., Harding H.P., Zhang Y., Ron D., et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005, 22:633-642.
22. Oz H.S., Chen T.S., McClain C.J., de Villiers W.J. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem 2005, 16:297-304.
23. Sido B., Hack V., Hochlehnert A., Lipps H., Herfarth C., Droge W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 1998, 42:485-492.
24. Goda K., Hamane Y., Kishimoto R., Ogishi Y. Radical scavenging properties of tryptophan metabolites. Estimation of their radical reactivity. Adv Exp Med Biol 1999, 467:397-402.
25. Suzen S. Antioxidant activities of synthetic indole derivatives and possible activity mechanisms. Bioactive heterocyles V, topics in heterocyclic chemistry 2007, Vol. 11:145-178. Springer, New York. R. Gupta, H. Khan (Eds.).
26. Bassaganya-Riera J., Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 2006, 25:454-465.
27. Mackenzie M.L., Warren M.R., Wykes L.J. Colitis increases albumin synthesis at the expense of muscle protein synthesis in macronutrient-restricted piglets. J Nutr 2003, 133:1875-1881.
28. National Research Council Nutrient requirements of swine 1998, Academy Press, Washington (DC). 10th ed.
29. Thymann T., Burrin D.G., Tappenden K.A., Bjornvad C.R., Jensen S.K., Sangild P.T. Formula-feeding reduces lactose digestive capacity in neonatal pigs. Br J Nutr 2006, 95:1075-1081.
30. Twombly R. Decoding the cryptic origins of colon cancer. Environ Health Perspect 2002, 110:A394-A395.
31. Rozen S., Skaletsky H.J. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics methods and protocols: methods in molecular biology 2000, 365-386. Humana Press, Totowa. S. Krawetz, S. Misener (Eds.).
32. Klein S., Meyers S., O'Sullivan P., Barton D., Leleiko N., Janowitz H.D. The metabolic impact of active ulcerative colitis. Energy expenditure and nitrogen balance. J Clin Gastroenterol 1988, 10:34-40.
33. Rigaud D., Angel L.A., Cerf M., Carduner M.J., Melchior J.C., Sautier C., et al. Mechanisms of decreased food intake during weight loss in adult Crohn's disease patients without obvious malabsorption. Am J Clin Nutr 1994, 60:775-781.
34. Poritz L.S., Garver K.I., Green C., Fitzpatrick L., Ruggiero F., Koltun W.A. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res 2007, 140:12-19.
35. Bruewer M., Luegering A., Kucharzik T., Parkos C.A., Madara J.L., Hopkins A.M., et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003, 171:6164-6172.
36. Kwon K.H., Murakami A., Tanaka T., Ohigashi H. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem Pharmacol 2005, 69:395-406.
37. Umehara Y., Kudo M., Nakaoka R., Kawasaki T., Shiomi M. Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis. Hepatogastroenterology 2006, 53:879-882.
38. Nielsen O.H., Kirman I., Rudiger N., Hendel J., Vainer B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol 2003, 38:180-185.
39. Van Assche G., Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2005, 288:G169-G174.
40. Hamamoto N., Maemura K., Hirata I., Murano M., Sasaki S., Katsu K. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol 1999, 117:462-468.
41. Taniguchi T., Tsukada H., Nakamura H., Kodama M., Fukuda K., Saito T., et al. Effects of the anti-ICAM-1 monoclonal antibody on dextran sodium sulphate-induced colitis in rats. J Gastroenterol Hepatol 1998, 13:945-949.
42. Williams K.L., Fuller C.R., Dieleman L.A., DaCosta C.M., Haldeman K.M., Sartor R.B., et al. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001, 120:925-937.
43. Garside P. Cytokines in experimental colitis. Clin Exp Immunol 1999, 118:337-339.
44. Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000, 51:289-298.
45. Begue B., Wajant H., Bambou J.C., Dubuquoy L., Siegmund D., Beaulieu J.F., et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006, 130:1962-1974.
46. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
47. Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999, 116:22-28.
48. Sanchez-Munoz F., Dominguez-Lopez A., Yamamoto-Furusho J.K. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008, 14:4280-4288.
49. Andoh A., Yagi Y., Shioya M., Nishida A., Tsujikawa T., Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008, 14:5154-5161.
50. Mizoguchi A., Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol 2008, 43:1-17.
51. Carlin J.M., Borden E.C., Sondel P.M., Byrne G.I. Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 1987, 139:2414-2418.
52. Melchior D., Meziere N., Seve B., Le Floc'h N. Is tryptophan catabolism increased under indoleamine 2,3 dioxygenase activity during chronic lung inflammation in pigs?. Reprod Nutr Dev 2005, 45:175-183.
53. Moffett J.R., Namboodiri M.A. Tryptophan and the immune response. Immunol Cell Biol 2003, 81:247-265.
54. Mellor A.L., Baban B., Chandler P., Marshall B., Jhaver K., Hansen A., et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003, 171:1652-1655.
55. Mellor A.L., Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4:762-774.
56. Doering J., Begue B., Lentze M.J., Rieux-Laucat F., Goulet O., Schmitz J., et al. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease. Gut 2004, 53:1632-1638.
57. Bannerman D.D., Eiting K.T., Winn R.K., Harlan J.M. FLICE-like inhibitory protein (FLIP) protects against apoptosis and suppresses NF-kappaB activation induced by bacterial lipopolysaccharide. Am J Pathol 2004, 165:1423-1431.
58. Baker D.H. Comparative species utilization and toxicity of sulfur amino acids. J Nutr 2006, 136:1670S-1675S.